Johnson & Johnson $JNJ Stock Holdings Cut by Hall Laurie J Trustee

Hall Laurie J Trustee reduced its position in shares of Johnson & Johnson (NYSE:JNJ) by 7.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 27,880 shares of the company’s stock after selling 2,282 shares during the period. Johnson & Johnson accounts for about 2.3% of Hall Laurie J Trustee’s holdings, making the stock its 15th biggest position. Hall Laurie J Trustee’s holdings in Johnson & Johnson were worth $7,381,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in JNJ. Wellington Management Group LLP lifted its position in shares of Johnson & Johnson by 12.5% during the 2nd quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company’s stock worth $5,736,851,000 after buying an additional 2,513,321 shares in the last quarter. Deutsche Bank AG increased its position in shares of Johnson & Johnson by 8.5% during the second quarter. Deutsche Bank AG now owns 15,661,323 shares of the company’s stock valued at $3,977,506,000 after acquiring an additional 1,225,676 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Johnson & Johnson by 8.7% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 17,275,937 shares of the company’s stock worth $3,575,255,000 after acquiring an additional 1,376,828 shares during the period. Amundi boosted its position in Johnson & Johnson by 17.5% in the first quarter. Amundi now owns 13,406,820 shares of the company’s stock worth $3,277,163,000 after purchasing an additional 2,001,139 shares during the last quarter. Finally, Nuveen LLC grew its position in Johnson & Johnson by 6.9% during the fourth quarter. Nuveen LLC now owns 10,609,171 shares of the company’s stock valued at $2,195,568,000 after buying an additional 683,967 shares during the period. 69.55% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

JNJ has been the topic of several research reports. HSBC lifted their price objective on shares of Johnson & Johnson from $290.00 to $320.00 and gave the stock a “buy” rating in a research report on Thursday, September 10th. Stifel Nicolaus set a $260.00 price objective on Johnson & Johnson in a research note on Wednesday, July 15th. Wall Street Zen downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. TD Cowen upped their price target on Johnson & Johnson from $250.00 to $300.00 and gave the company a “buy” rating in a research report on Monday, July 13th. Finally, Weiss Ratings raised Johnson & Johnson from a “buy (b-)” rating to a “buy (b)” rating in a report on Friday, July 24th. One research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $276.22.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Vanessa Broadhurst sold 23,054 shares of the company’s stock in a transaction on Monday, July 20th. The shares were sold at an average price of $251.27, for a total value of $5,792,778.58. Following the completion of the sale, the executive vice president owned 23,003 shares of the company’s stock, valued at approximately $5,779,963.81. This represents a 50.06% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Jennifer Taubert sold 15,000 shares of the stock in a transaction on Monday, August 17th. The shares were sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the transaction, the executive vice president directly owned 194,451 shares in the company, valued at approximately $51,210,615.36. This represents a 7.16% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 87,569 shares of company stock valued at $23,064,544. Insiders own 0.16% of the company’s stock.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: RBC Capital Markets said accelerating performance in J&J’s Innovative Medicine segment is offsetting persistent MedTech headwinds. The assessment supports the view that new drug launches and portfolio diversification can help sustain growth. Johnson & Johnson’s Innovative Medicines Momentum Offsets MedTech Headwinds
• Positive Sentiment: Analyst comparisons with Pfizer continue to favor J&J’s diversified portfolio, sales growth and new product pipeline, despite Pfizer’s lower valuation and higher dividend yield. Pfizer vs. J&J: Comparing Growth, Patent Risks and Valuation
• Positive Sentiment: J&J remains attractive to income-oriented and defensive investors because healthcare demand is expected to remain relatively resilient during an economic downturn. Its long-term dividend reliability is also being highlighted in comparisons with Procter & Gamble. Looking for a Dividend Stock That Can Weather a Downturn?
• Neutral Sentiment: CEO Joaquin Duato said artificial intelligence should be embraced as a “force multiplier.” The comments point to potential long-term productivity and innovation benefits, but provide no near-term earnings update. Johnson & Johnson CEO Says AI Has to Be Embraced
• Negative Sentiment: MedTech’s rebound is uncertain after a second-quarter slowdown. Abiomed-related and broader competitive pressures could weigh on results, although Vision, Orthopedics and Surgery may improve in the second half. Can J&J’s MedTech Business Rebound in Q3?
• Negative Sentiment: Investors remain focused on an estimated $4 billion patent cliff in 2027. The need to replace that revenue stream could matter more than a modest quarterly earnings beat and is contributing to recent caution ahead of the report. Why a $4 Billion 2027 Patent Cliff Matters

Johnson & Johnson Stock Performance

JNJ stock traded up $1.92 during midday trading on Tuesday, reaching $254.85. 5,660,663 shares of the company’s stock traded hands, compared to its average volume of 7,994,485. Johnson & Johnson has a 52 week low of $182.94 and a 52 week high of $281.07. The company has a 50-day moving average price of $266.10 and a two-hundred day moving average price of $248.51. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09. The firm has a market capitalization of $614.17 billion, a PE ratio of 29.53, a price-to-earnings-growth ratio of 2.52 and a beta of 0.21.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.84 by $0.06. The company had revenue of $25.31 billion during the quarter, compared to analysts’ expectations of $25.06 billion. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The firm’s quarterly revenue was up 6.6% compared to the same quarter last year. During the same period in the previous year, the business earned $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, equities analysts anticipate that Johnson & Johnson will post 11.54 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th were paid a dividend of $1.34 per share. The ex-dividend date of this dividend was Tuesday, August 25th. This represents a $5.36 annualized dividend and a dividend yield of 2.1%. Johnson & Johnson’s dividend payout ratio (DPR) is 62.11%.

About Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.